Pre-Conference Speaker(s)

  • Andrew Talal, MD, MPH

    Professor, Department of Medicine Director, Center for Research and Clinical Care in Liver Disease Jacobs School of Medicine and Biomedical Sciences
    University at Buffalo

  • Stevan Gonzalez, MD, MS

    Associate Professor Department of Internal Medicine Texas A&M College of Medicine Medical Director of Liver Transplantation Simmons Transplant Institute
    TCU and UNTHSC School of Medicine

  • Douglas Dieterich, MD

    Director, Institute of Liver Medicine Professor of Medicine Division of Liver Disease Department of Medicine
    Icahn School of Medicine

  • Grant Mitchell, MD

    Chair, Department of Psychiatry Associate Professor of Psychiatry, Icahn School of Medicine at Mount Sinai
    Mount Sinai Beth Israel

The symposia series will feature didactic and clinical case discussions on the hepatitis C virus (HCV) as it relates to patients suffering from substance use disorders (SUDs) and patients who use drugs (PWUD). The program chair will comment on presentations, reinforce key learnings and use real-time feedback to support teaching points that address the core educational objectives of the program. The expert panel will use current guidelines and the latest clinical evidence to support their opinions on incorporating new therapeutic options for patient management.

Learning Objectives:

  • Discuss data on the incidence, prevalence and transmission of HCV in persons who use drugs (PWUD)
  • Describe the detrimental effects of chronic HCV, including the extrahepatic manifestations, to emphasize the need for diagnosis and treatment in PWUD
  • Discuss updates in screening mandates and treatment guidelines for HCV including the importance of harm reduction and prevention of reinfect